Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics Inc has demonstrated significant revenue potential with an impressive increase in net revenue projections for 4Q from $4.5 million to $16.2 million, driven by a 40% growth in October prescriptions compared to the previous month. The company has reported a strong momentum in prescription growth, with 2,189 units prescribed in October alone, marking a 41% sequential increase that exceeded the third quarter's total prescription volume. Furthermore, Pelthos is enhancing its market presence by expanding its sales force from 50 to 64 territory managers, targeting an increase in coverage to approximately 10,000 clinicians, which could lead to substantial revenue growth from its existing commercial model.

Bears say

Pelthos Therapeutics Inc faces significant challenges that present a negative outlook for its stock. Key risks include potential inadequacies in securing reimbursement and formulary placements, which may hinder market uptake and adversely impact sales and profit margins. Additionally, competitive pressures from other products and potential operational disruptions, such as supply chain issues or failures in clinical trials, could further impede revenue growth and overall financial stability.

PTHS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Strong Buy based on their latest research and market trends.

According to 4 analysts, PTHS has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.